Erik Corcoran

859 total citations
12 papers, 481 citations indexed

About

Erik Corcoran is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Erik Corcoran has authored 12 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Infectious Diseases. Recurrent topics in Erik Corcoran's work include Angiogenesis and VEGF in Cancer (5 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Erik Corcoran is often cited by papers focused on Angiogenesis and VEGF in Cancer (5 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Erik Corcoran collaborates with scholars based in United States. Erik Corcoran's co-authors include James R. Tonra, Daniel J. Hicklin, Dhanvanthri S. Deevi, Huiling Li, Su Wang, Francine E. Carrick, Elizabeth Navarro, Yan Wu, Dale L. Ludwig and Henry Koo and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Erik Corcoran

12 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Corcoran United States 9 215 189 89 86 84 12 481
Leanne Cartee United States 14 357 1.7× 226 1.2× 94 1.1× 99 1.2× 47 0.6× 27 646
Daniela De Martino Italy 12 198 0.9× 137 0.7× 36 0.4× 47 0.5× 66 0.8× 15 475
Deepu Alex United States 15 221 1.0× 195 1.0× 184 2.1× 253 2.9× 108 1.3× 30 766
Susan D. Mertins United States 11 479 2.2× 236 1.2× 64 0.7× 64 0.7× 103 1.2× 16 797
Sanhua Wei China 11 324 1.5× 121 0.6× 46 0.5× 27 0.3× 64 0.8× 22 517
Ben Zhao China 8 151 0.7× 218 1.2× 103 1.2× 78 0.9× 87 1.0× 17 517
Siddhartha Dutta Gupta India 15 431 2.0× 155 0.8× 29 0.3× 100 1.2× 113 1.3× 24 811
Paulina Gronesova Slovakia 15 258 1.2× 199 1.1× 53 0.6× 73 0.8× 149 1.8× 38 601
Frédéric Couture Canada 14 358 1.7× 157 0.8× 44 0.5× 58 0.7× 87 1.0× 38 597
Charles E. Gast United States 8 154 0.7× 160 0.8× 142 1.6× 35 0.4× 70 0.8× 9 473

Countries citing papers authored by Erik Corcoran

Since Specialization
Citations

This map shows the geographic impact of Erik Corcoran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Corcoran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Corcoran more than expected).

Fields of papers citing papers by Erik Corcoran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Corcoran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Corcoran. The network helps show where Erik Corcoran may publish in the future.

Co-authorship network of co-authors of Erik Corcoran

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Corcoran. A scholar is included among the top collaborators of Erik Corcoran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Corcoran. Erik Corcoran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Molony, Ryan D., Gina M. Trabucco, Erik Corcoran, et al.. (2022). CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses. Frontiers in Immunology. 13. 909979–909979. 3 indexed citations
2.
Duignan, Inga, Erik Corcoran, Mary Jane Plym, et al.. (2011). Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models. Neoplasia. 13(1). 49–59. 14 indexed citations
3.
Surguladze, David, Dhanvanthri S. Deevi, Erik Corcoran, et al.. (2009). Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice. Cancer Research. 69(14). 5643–5647. 40 indexed citations
4.
Tonra, James R., Erik Corcoran, Dhanvanthri S. Deevi, et al.. (2009). Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.. PubMed. 29(6). 1999–2007. 8 indexed citations
5.
Tonra, James R., Marie Prewett, Erik Corcoran, Daniel J. Hicklin, & Zhenping Zhu. (2008). In Vivo Method for Establishing Synergy Between Antibodies to Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2. Methods in molecular biology. 525. 545–557. 1 indexed citations
6.
Griffith, David C., David Rodríguez, Erik Corcoran, & Michael N. Dudley. (2007). Pharmacodynamics of RWJ-54428 against Staphylococcus aureus , Streptococcus pneumoniae , and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 52(1). 244–247. 9 indexed citations
7.
Tonra, James R., Dhanvanthri S. Deevi, Erik Corcoran, et al.. (2006). Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy. Clinical Cancer Research. 12(7). 2197–2207. 127 indexed citations
8.
9.
Tonra, James R., Dhanvanthri S. Deevi, Erik Corcoran, et al.. (2006). 207 POSTER Combined antibody mediated inhibition of IFG-IR, EGFR, and VEGFR2 for more consistent and greater antitumor effects. European Journal of Cancer Supplements. 4(12). 64–65. 3 indexed citations
10.
Wu, Yan, Zhaojing Zhong, James Huber, et al.. (2006). Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer. Clinical Cancer Research. 12(21). 6573–6584. 120 indexed citations
11.
Pan, Weitao, Hua‐Quan Miao, Yongjiang Xu, et al.. (2005). 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(2). 409–412. 53 indexed citations
12.
Cacciapuoti, Anthony, David Loebenberg, Erik Corcoran, et al.. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy. 44(8). 2017–2022. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leanne Cartee Breakdown of academic impact, for papers by Daniela De Martino Breakdown of academic impact, for papers by Deepu Alex Breakdown of academic impact, for papers by Susan D. Mertins Breakdown of academic impact, for papers by Sanhua Wei Breakdown of academic impact, for papers by Ben Zhao Breakdown of academic impact, for papers by Siddhartha Dutta Gupta Breakdown of academic impact, for papers by Paulina Gronesova Breakdown of academic impact, for papers by Frédéric Couture Breakdown of academic impact, for papers by Charles E. Gast
Rankless by CCL
2026